Russell Z. Szmulewitz

Associate Professor
Biosciences Graduate Program Association
  1. PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate resistant prostate cancer. Clin Cancer Res. 2023 Mar 10. View in: PubMed

  2. Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review. Ther Adv Med Oncol. 2023; 15:17588359221149887. View in: PubMed

  3. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res. 2023 01 04; 29(1):50-59. View in: PubMed

  4. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. Prostate Cancer. 2022; 2022:5454727. View in: PubMed

  5. Editorial Comment. J Urol. 2022 11; 208(5):996. View in: PubMed

  6. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate. 2022 09; 82(13):1237-1247. View in: PubMed

  7. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 05 20; 40(15):1616-1622. View in: PubMed

  8. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1531-1539. View in: PubMed

  9. Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 2022 Feb; 41(8):1234. View in: PubMed

  10. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559. View in: PubMed

  11. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 2022 02; 41(8):1190-1202. View in: PubMed

  12. Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. Support Care Cancer. 2022 Mar; 30(3):2803-2810. View in: PubMed

  13. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021 08; 9(8). View in: PubMed

  14. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2022 02; 25(2):274-282. View in: PubMed

  15. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2021 06; 150:83-94. View in: PubMed

  16. A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640. View in: PubMed

  17. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021 07 15; 27(14):4077-4088. View in: PubMed

  18. Reply by Authors. J Urol. 2021 05; 205(5):1371. View in: PubMed

  19. The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check. JAMA Oncol. 2021 06 01; 7(6):827-828. View in: PubMed

  20. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 04 20; 39(12):1371-1382. View in: PubMed

  21. Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer. 2021 06 01; 127(11):1827-1835. View in: PubMed

  22. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. J Urol. 2021 May; 205(5):1361-1371. View in: PubMed

  23. Prog Urol. 2020 Nov; 30(13):745. View in: PubMed

  24. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2020; 4. View in: PubMed

  25. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050. View in: PubMed

  26. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. J Pharmacol Exp Ther. 2020 09; 374(3):438-451. View in: PubMed

  27. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 10; 78(4):603-614. View in: PubMed

  28. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019 12 20; 37(36):3518-3527. View in: PubMed

  29. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 03 15; 26(6):1247-1257. View in: PubMed

  30. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate. 2019 11; 79(15):1752-1761. View in: PubMed

  31. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clin Cancer Res. 2019 11 01; 25(21):6309-6319. View in: PubMed

  32. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 11 10; 37(32):2974-2986. View in: PubMed

  33. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist. 2019 09; 24(9):1151-e817. View in: PubMed

  34. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol. 2019 05 01; 37(13):1120-1129. View in: PubMed

  35. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18. View in: PubMed

  36. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):43-51. View in: PubMed

  37. Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061. View in: PubMed

  38. Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. J Clin Oncol. 2018 10 20; 36(30):3064-3065. View in: PubMed

  39. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 10; 36(5):919-926. View in: PubMed

  40. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res. 2018 08 01; 24(15):3668-3680. View in: PubMed

  41. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24. View in: PubMed

  42. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395. View in: PubMed

  43. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth. Mol Cancer Ther. 2017 08; 16(8):1680-1692. View in: PubMed

  44. Sequential phase II studies for endometrial cancer (EC): Pegylated liposomal doxorubicin (LD) with either paclitaxel (P) or docetaxel (D). J Clin Oncol. 2005 Jun; 23(16_suppl):5134. View in: PubMed

  45. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. Prostate. 2017 03; 77(4):385-395. View in: PubMed

  46. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212. View in: PubMed

  47. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget. 2016 May 03; 7(18):26259-74. View in: PubMed

  48. Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Sci. 2015 Jul; 1(1). View in: PubMed

  49. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93. View in: PubMed

  50. Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med. 2015 Sep 16; 7(305):305ps19. View in: PubMed

  51. Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report. Front Oncol. 2015; 5:169. View in: PubMed

  52. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014 Nov 26; 12:313. View in: PubMed

  53. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. View in: PubMed

  54. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate. 2014 Nov; 74(15):1530-43. View in: PubMed

  55. Corticosteroids and prostate cancer: friend or foe? Eur Urol. 2015 May; 67(5):874-5. View in: PubMed

  56. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7. View in: PubMed

  57. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91. View in: PubMed

  58. Vemurafenib oral bioavailability: an insoluble problem. J Clin Pharmacol. 2014 Apr; 54(4):375-7. View in: PubMed

  59. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr; 5(2):72-89. View in: PubMed

  60. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8. View in: PubMed

  61. Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2013 Mar; 93(3):242-4. View in: PubMed

  62. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One. 2013; 8(1):e53701. View in: PubMed

  63. A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer. Eur Urol. 2012 Nov; 62(5):864-6. View in: PubMed

  64. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92. View in: PubMed

  65. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012 Feb 01; 72(2):157-64. View in: PubMed

  66. Metastasis-suppressor genes in clinical practice: lost in translation? Nat Rev Clin Oncol. 2011 Jun; 8(6):333-42. View in: PubMed

  67. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum. Semin Oncol. 2011 Apr; 38(2):309-25. View in: PubMed

  68. MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. Int J Cancer. 2012 Feb 01; 130(3):509-20. View in: PubMed

  69. Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies. Indian J Urol. 2010 Jan-Mar; 26(1):92-7. View in: PubMed

  70. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103. View in: PubMed

  71. New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett. 2008 Dec 08; 272(1):12-22. View in: PubMed

  72. Sunitinib--a new standard of care for metastatic renal cell carcinoma. Nat Clin Pract Oncol. 2007 Aug; 4(8):458-9. View in: PubMed

  73. Resistance to thyroid hormone does not abrogate the transient thyrotoxicosis associated with gestation: report of a case. J Clin Endocrinol Metab. 2001 Sep; 86(9):4273-5. View in: PubMed